We hope that the comments below will prove constructive as your work progresses.
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A. THESE ITEMS ARE REQUIRED FOR REVISIONS
--A letter addressing the reviewers' comments point by point.
--An editable version of the final text (.DOC or .DOCX) is needed for copyediting (no PDFs).
--High-resolution figure, supplementary figure and video files uploaded as individual files: See our detailed guidelines for preparing your production-ready images, http://life-sciencealliance.org/authorguide --Summary blurb (enter in submission system): A short text summarizing in a single sentence the study (max. 200 characters including spaces). This text is used in conjunction with the titles of papers, hence should be informative and complementary to the title and running title. It should describe the context and significance of the findings for a general readership; it should be written in the present tense and refer to the work in the third person. Author names should not be mentioned.
B. MANUSCRIPT ORGANIZATION AND FORMATTING:
Full guidelines are available on our Instructions for Authors page, http://life-sciencealliance.org/authorguide We encourage our authors to provide original source data, particularly uncropped/-processed electrophoretic blots and spreadsheets for the main figures of the manuscript. If you would like to add source data, we would welcome one PDF/Excel-file per figure for this information. These files will be linked online as supplementary "Source Data" files. ***IMPORTANT: It is Life Science Alliance policy that if requested, original data images must be made available. Failure to provide original images upon request will result in unavoidable delays in publication. Please ensure that you have access to all original microscopy and blot data images before submitting your revision.***
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Reviewer #1 (Comments to the Authors (Required)):
In this MS, the authors report the discovery of IRC117539 that purportedly both inhibit AR activity and target it for degradation. I think the results of this molecule is important and should be published. However, the current MS does not convincingly show that inhibits tumor growth through AR inhibition, and that it either degrades AR or it inhibits proteasomes at relevant in vivo exposure. 1. In general, please add drug concentrations to figure legends or to figure itself (Fig 2, Fig 3) to make it easier to assess. 2. In Fig. 1 , it is unexpected and intriguing that IRC117539 is toxic to 22Rv1 cells, which his intrinsically resistant to enzalutamide due to expression of ARv7 variant. This suggests that IRC117539 has either 1. Off target activity, or 2. Inhibit AR in a LBD independent manner. Please delineate. 3. Several compounds are purported to degrade AR, including some that have gone onto trials. All of these degrade AR at a log-fold increase in concentration compared to that required to inhibit AR and they do not degrade AR in vivo and trials are not promising. Only fig 1 looks at a dose-response curve. Fig. 2 and Fig 3 also needs a dose-titration curve to compare dose of AR inhibition vs dose of proteasome inhibition and AR degradation. 4. The first timepoint is 24 hours. This is way too long for true changes in protein stability. Effect of MG132 on unstable proteins such as p53 can be appreciated by 30 minutes. Studying 24 and 48 hours would include many non-direct secondary effects. 5. Fig 4B, delayed effect is likely not due to AR inhibition. Is the high dose toxic to mice and are they losing weight? 6. Fig 4C is unconvincing for any AR degradation. For example, enzalutamide which does not actively degrade AR also significantly decrease AR nuclear staining in xenograft tumors (more than shown for IRC117539 here). Authors should just say that their drug does not significantly decrease AR protein in vivo. 7. For Fig 5, the dose tested to stabilize proteins is often much higher than therapeutic dose. So one cannot imply that this is happening in patients in vivo.
Reviewer #2 (Comments to the Authors (Required)):
The manuscript describes a novel rationally designed AR inhibitor which promotes AR degradation, IRC117539. The authors provide evidence that degradation is proteasomally dependent. The latter observation, based on MG132 treatment, is most clear at the 24-hour timepoint in Fig. 2B . The authors should comment on the less significant effect at 48 hours. Is this because the cells are dying or due to some other factor? Having established a high degree of specificity in a panel of PCa cell-lines in Fig.1 the manuscript then reports some off-target effects including inhibition of proteolysis as assayed through the accumulation of ubiquitin and Sumo conjugates. These data are shown in figure 3 and at this point some cell-lines are used which were not used in figure 1 including HeLa and WI38 cells. It would be helpful to know whether these effects are also observed in the AR-negative PCa cell-lines used in figure 1. It would be reciprocally be helpful to know what the IC50 values are for the two lines used in figure 3 (HeLa and WI38). In the context of figure 3 it would be helpful to know whether the effect of accumulating ubiquitin and Sumo conjugates is to trigger the activation of unfolded protein response pathways and whether that in turn is leading to cell death -markers such as ATF4 and CHOP could be used. It would also be helpful to know whether some or all of these changes are observed in harvested tumour tissue from subsequent xenograft experiments. Overall the manuscript is interesting but somewhat disjointed in its current form. A rather specific drug has some off-target effects but it is not entirely clear which dominate to determine the growth effects on cancer cells and consequently how significant the off-target effects might prove to be. Ensuring that many of the reported measurements are made across the full range of models used in the paper will help.
Thank you for submitting your manuscript entitled "Interference with proteasomes blunts growth inhibition resulting from androgen receptor degradation" to Life Science Alliance. The manuscript was assessed by expert reviewers, whose comments are appended to this letter.
As you will see, the reviewers find the identification of a new AR inhibitor important. However, they also point out some weaknesses in your dataset. Reviewer #1 thinks that more rigor is needed for analyses and data presentation, and that dose-titration curves should be provided as well as addressing that some results may be due to offtarget effects. This reviewer also points out that some of your conclusions need downtoning. Reviewer #2 thinks that the various cell lines analyzed should be used consistently in all assays, and that IC50 values need to get reported. This reviewer also notes that the two parts of your manuscript are too disconnected, and we agree with this view.
We would like to ask you to submit a revised version of your manuscript, addressing the above-mentioned issues. Maybe you have data at hand that may help connecting the two parts of your manuscript better, or, alternatively, you can perhaps find a good way to do so by changing the text.
When submitting the revision, please include a letter addressing the reviewers' comments point by point.
Thank you for this interesting contribution to Life Science Alliance. We are looking forward to receiving your revised manuscript. In this MS, the authors report the discovery of IRC117539 that purportedly both inhibit AR activity and target it for degradation. I think the results of this molecule is important and should be published. However, the current MS does not convincingly show that inhibits tumor growth through AR inhibition, and that it either degrades AR or it inhibits proteasomes at relevant in vivo exposure.
We thank the reviewer for appreciating the importance of our data on IRC117539. We have now extensively modified the manuscript, rigorously studied IRC117539 in various AR(+) and AR (-) (LNCaP, VCaP, PC3, Du145, HeLa, WI38) ( Fig 4A, Fig S4B, Fig S5) . Fig 1A, Fig 1B, Fig S1B) .
We did not observe proteasome inhibition in 22Rv1 cells (Fig S4C), and could not obtain data in MiaPaca2 cells due to technical challenges. Critically, IRC117539 consistently induced loss of viability only in AR-dependent PC cells (LNCaP, VCaP and 22Rv1) but not in others (
Of note, while survival of AR(-) PC3, Du145, HeLa, WI38 cells (which display proteasome inhibition) was not affected, AR(+) 22Rv1 cells lose viability (despite lack of proteasome inhibition). These observations strongly argue that loss of viability is uncoupled from proteasome inhibition, and that IRC117539's off-target effect on proteasomes per se does not lead to cell death.
In line with the notion that AR degradation initiates PC cell death, we could also successfully show that IRC117539 induces AR degradation also in VCaP and 22Rv1 cells (in the original manuscript, we had shown this only in LNCaP cells).
Thus, a) correlation between 'AR loss' and 'loss of viability' in all 3 AR(+) PC cells, b) uncoupling of proteasome inhibition from mortality, strongly argue that IRC117539's growth inhibitory effect on PC cells stems mainly from AR degradation, rather than off-target effects.
In fact, IRC117539 only mildly affects the proteasomes: IRC117539-induced accumulation of ubiquitinated proteins is mild when compared with a standard proteasome inhibitor such as MG132 (Fig S6C) . IRC117539 does not cause significant ER distress (Fig S6C) , and its IC50 on proteasomes is much higher than its IC50 on IC50(survival): 614 nM and IC50(proteasome): 878 μM) (Fig 1A and 4C ).
This unexpected weak off-target activity, though not inhibitory on cell survival, may antagonize drug's primary function and impede AR degradation in vivo.
Indeed, we observed signs of proteasome inhibition at relevant in vivo exposure in mice (Fig S4D) Fig 5) . (Fig 3B and 3C) . This catabolic pathway is intriguingly reminiscent of therapy-induced PML/RARA degradation in acute promyelocytic leukemia and therapy-induced Tax oncoprotein degradation in adult T-cell lymphoma. In both cases, drug-induced clearance of these oncoproteins results in growth inhibition of cancer cells.
Concerning the mechanism of IRC117539-induced AR degradation, we now corroborated our initial proximity ligation analyses (PLA) with robust immunoprecipitation data. IRC117539 clearly induces massive SUMO(2/3)ylation of endogenous AR in LNCaP cells, which seems to be a prerequisite for its degradation
1. In general, please add drug concentrations to figure legends or to figure itself (Fig 2, Fig 3) to make it easier to assess. Fig 4 (old Fig 3) now shows data on LNCaP, VCaP, PC3 and Du145 cells. Fig. 1 , it is unexpected and intriguing that IRC117539 is toxic to 22Rv1 cells, which his intrinsically resistant to enzalutamide due to expression of ARv7 variant. This suggests that IRC117539 has either 1. Off target activity, or 2. Inhibit AR in a LBD independent manner. Please delineate. (Centenera et al., 2008) . Based on any of these modes, it is conceivable that ARv7 may dimerize with a full-length (FL) AR, which is also expressed in 22Rv1 cells (Fig 2A and Cunningham and You, 2015; Dehm et al., 2008) . Indeed, truncated AR variants were recently shown to not only homodimerize with each other but also heterodimerize with full-length AR (Xu et al., 2015 (Fig 2A) (Fig S6D) .
Drug concentrations are now indicated on both main and supplementary figures and/or legends. Please note that Fig 2 now shows data from LNCaP, VCaP and 22Rv1 cells and
In
We thank the reviewer for raising this interesting point. 22Rv1 cells are indeed ARdependent, yet androgen insensitive because they express the truncated AR variant (ARv7). AR dimerizes to initiate target gene transcription. Several modes of AR dimerization have been proposed, including dimerization through interactions between N-terminus/C-terminus and dimerization through DNA-binding domain
This is a valid point and we appreciate the value of proposed comparisons. We have now added dose-response curves for AR degradation (Fig 2B) and proteasome inhibition (Fig 4B and 4C) for comparison with AR inhibition and cell survival curves in Fig 1. Importantly and contrary to previously reported compounds, IRC117539 achieves full AR degradation at doses comparable to those required for AR inhibition and survival impairment (around or less than 1000 nM). On the other hand, a log-fold increase in concentration is needed for proteasome inhibition, at least ex vivo in cultured cells
The first timepoint is 24
hours. This is way too long for true changes in protein stability. Effect of MG132 on unstable proteins such as p53 can be appreciated by 30 minutes. Studying 24 and 48 hours would include many non-direct secondary effects. (Fig 2A  and 2B) . In Fig 4, (Fig 4), b) the effect of MG132 on unstable ubiquitin conjugates was more pronounced than that of IRC117539 (Fig S6C) . Fig 4B, delayed effect 
We agree with the reviewer. Therefore, we now show data and statistical analyses for 6, 12, 24 and 48 hrs. We observe significant AR degradation as early as 6 hrs upon treatment, which reaches near completion by 12 hrs in LNCaP cells
we also studied accumulation of ubiquitinated proteins at earlier time points. Consistent with IRC117539 being a mild inhibitor of the proteasome, a) significant accumulation was observed only at later time points (upon prolonged treatment) in most cell lines
5.
We agree with the reviewer that the kinetics of IRC117539's effect is different from that of MDV3100. We tend to see this as a difference in the mechanism of action. Inhibition of AR pathway is less strong with IRC117539, which requires AR degradation, which, in turn, takes time. In addition, we also take into account the different pharmacokinetics of these molecules, as it simply takes more time for IRC to reach and keep inhibitory concentrations in tumors.
6. Fig 4C is unconvincing for Fig 5C) and neither…" 7. For Fig 5, the dose tested to stabilize proteins is often much higher than therapeutic dose. So one cannot imply that this is happening in patients in vivo. Fig 1A; added dose-response curves/or IC50 values for AR degradation (Fig 2B) and proteasome inhibition (Fig 4B and 4C) Fig 5) .
We agree with the reviewer. Following our discussions with the editor and in order to improve both the flow and the integrity of the manuscript, we have now removed old Fig 5, and decided to focus entirely on IRC117539 and its mechanism of action.
Reviewer #2 (Comments to the Authors (Required)):
We thank this reviewer for expressing his/her interest in our manuscript, which we have considerably improved. We have now used the panel of prostate cancer (PC) cell lines introduced in Fig 1A in a more consistent manner; obtained robust data on AR degradation in 3 different PC lines; further explored the mechanism underlying AR degradation; studied IRC117539's off-target effect in most of the cell lines shown in
The manuscript describes a novel rationally designed AR inhibitor which promotes AR degradation, IRC117539. The authors provide evidence that degradation is proteasomally dependent. The latter observation, based on MG132 treatment, is most clear at the 24-hour timepoint in Fig. 2B . The authors should comment on the less significant effect at 48 hours. Is this because the cells are dying or due to some other factor?
The reviewer is correct in that in previous Fig 2B, Fig 2A, 2B and 2C ). (Fig 1B) , adding MG132 at this point only introduced further toxicity. We performed this experiment several times, also including an earlier time point at 6 hrs, and consistently observed that MG132 prevented IRC117539-induced AR degradation as long as it was present during IRC117539 treatment (please see new Fig 2C) . Below, we show the uncropped gel to the reviewer, but for simplicity we chose to omit the 48 hrs time point in the paper. Finally, in line with proteasome-dependent degradation of AR, we could show that PD169316, a small molecule proteasome activity booster, significantly enhanced IRC117539-induced AR degradation (Fig 2D) . Fig.1 the manuscript then reports some off-target effects including inhibition of proteolysis as assayed through the accumulation of ubiquitin and Sumo conjugates. These data are shown in figure 3 and at this point some cell-lines are used which were not used in figure 1 including HeLa and WI38 cells. it would be helpful to know whether these effects are also observed in the AR-negative PCa cell-lines used in figure 1. Fig 1A, 
In addition, IRC117539 treatment induces death in LNCaP cells
Having established a high degree of specificity in a panel of PCa cell-lines in
We agree with the reviewer and appreciate the value of the proposed experiment. New Figs 4A and S4B now show drug's effect on global proteolysis in two of the ARnegative PC lines (PC3 and Du145) mentioned in
as well as in two ARpositive PC lines (LNCaP and VCaP). We could not obtain further data in MiaPaca2 cells due to technical reasons (contamination).
To answer the reviewer's question, both of the AR-negative PC lines (PC3 and Du145) displayed accumulation of global ubiquitin/SUMO conjugates.
We did not observe proteasome inhibition in 22Rv1 cells (Fig S4C) . Critically, IRC117539 consistently induced loss of viability only in VCaP and 22Rv1) but not in others (Fig 1A, Fig 1B, Fig S1B) figure 3 (HeLa and WI38) . Fig 1A, survival of these two cell types was also only slightly affected by the compound.
We agree with the reviewer and now show the IC50 values for HeLa and WI38 cells in Fig S1B. As in other AR(-) cell lines used in
Kindly note that to ensure consistency, in new Fig 4 (old Fig 3) , we show data from two of the In the context of figure 3 it would be helpful to know whether the effect of accumulating ubiquitin and Sumo conjugates is to trigger the activation of unfolded protein response pathways and whether that in turn is leading to cell death -markers such as ATF4 and CHOP could be used. It would also be helpful to know whether some or all of these changes are observed in harvested tumour tissue from subsequent xenograft experiments.
We thank the reviewer for this suggestion and now tested two UPR markers that were available to us: CHOP and BiP (Fig S6C) (Fig S6C) . Also, its IC50 on proteasomes is much higher than its IC50 on IC50(survival): 614 nM and IC50(proteasome): 878 μM) (Fig 1A and 4C) (Fig S4D) .
Overall the manuscript is interesting but somewhat disjointed in its current form. A rather specific drug has some off-target effects but it is not entirely clear which dominate to determine the growth effects on cancer cells and consequently how significant the off-target effects might prove to be. Ensuring that many of the reported measurements are made across the full range of models used in the paper will help. 2) by performing rigorous data analyses. We have now added dose-response curves for AR degradation (Fig 2B) and proteasome inhibition (Fig 4B, and IC50 in 4C) for comparison with AR inhibition and survival curves in Fig 1. (Fig S6D) . (Fig 3B and 3C) (Fig 2D), b) IRC117539 is a promising compound and may offer the possibility to target Fig 1A and 2A) , and it may further be improved by screening out its undesired effect on proteasomes.
Again
Critically, IRC117539 achieves full AR degradation at doses comparable to those required for AR inhibition and survival impairment (around or less than 1000 nM). On the other hand, a log-fold increase in concentration is needed for proteasome inhibition, at least ex vivo in cultured cells
3) by showing that IRC117539-induced PC cell death is uncoupled from its effect on
